Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Februar 2020

Planlagt Fastgjort Låst Flyttet Genmab
1.7k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #141

    Recruitment Status : Withdrawn (Business Reasons) https://clinicaltrials.gov/ct2/show/NCT03221634

    1 Reply Last reply
    0
    • BulderB Offline
      BulderB Offline
      Bulder
      wrote on sidst redigeret af
      #142

      Lego: Atezo ejes af Roche. BMS ejer Opdivo - nivolumab

      1 Reply Last reply
      0
      • BulderB Offline
        BulderB Offline
        Bulder
        wrote on sidst redigeret af
        #143

        Nu vi snakker om BMS: "Den amerikanske medicinalkoncern Bristol-Myers Squibb, der for nyligt har gennemført det 74 mia. dollar store opkøb af biotekselskabet Celgene, har torsdag aflagt regnskab for fjerde kvartal, hvor indtjeningen overrasker positivt, mens prognoserne for 2020 er lidt til den svage side.
        Aktien indikeres dog 3,0 pct. højere i det amerikanske formarked."

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #144

          article by your local Dara / MM hero...

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #145

            Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad? https://www.mdpi.com/2073-4409/9/2/378

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #146

              pdf
              https://sci-hub.tw/https://www.mdpi.com/2073-4409/9/2/378

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #147

                part of Special Issue "CD38 and Disease: A Bi-Directional Cross-Talk between Pathology and Physiology" https://www.mdpi.com/journal/cells/special_issues/CD38_CD157

                1 Reply Last reply
                0
                • BulderB Offline
                  BulderB Offline
                  Bulder
                  wrote on sidst redigeret af
                  #148

                  I don't quite get the point here. Do they recommend a dara-break or not?

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #149

                    i think they recomend more research before they can decide that...?

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #150

                      it amazed me before, how much is still unknown about the workings of a drug that sells $3bn a year...

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #151

                        this part has focus on CD38 in Solid Tumors https://www.mdpi.com/2073-4409/9/1/52/htm

                        1 Reply Last reply
                        0
                        • DarvinD Offline
                          DarvinD Offline
                          Darvin
                          wrote on sidst redigeret af
                          #152

                          1637 - er det så rødvin igen. Det går altså ikke 😉

                          1 Reply Last reply
                          0
                          • SolsenS Offline
                            SolsenS Offline
                            Solsen
                            wrote on sidst redigeret af
                            #153

                            🙂

                            1 Reply Last reply
                            0
                            • J Offline
                              J Offline
                              JKY_VH
                              wrote on sidst redigeret af
                              #154

                              Du har ret Darvin, men på den anden side set så kunne der ske værre ting end at Genmab sætter endnu en kursrekord:-)

                              1 Reply Last reply
                              0
                              • DarvinD Offline
                                DarvinD Offline
                                Darvin
                                wrote on sidst redigeret af
                                #155

                                Enig - lad dem bare komme - en efter en, og et par trin tilbage tager vi såmænd
                                også med

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Sukkeralf
                                  wrote on sidst redigeret af
                                  #156

                                  Tisotumab Vedotin Program Highlights

                                  Tisotumab Vedotin innovaTV 204 Pivotal Trial Data Expected in 2020: Seattle Genetics and Genmab expect to report topline data in the first half of 2020 from the innovaTV 204 pivotal trial of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard-of-care treatment.

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Sukkeralf
                                    wrote on sidst redigeret af
                                    #157

                                    Just a moment...

                                    favicon

                                    (www.firstwordpharma.com)

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Sukkeralf
                                      wrote on sidst redigeret af
                                      #158

                                      Så ikke rigtig noget nyt derfra !

                                      1 Reply Last reply
                                      0
                                      • Helge_LarsenPI-redaktørH Offline
                                        Helge_LarsenPI-redaktørH Offline
                                        Helge_LarsenPI-redaktør
                                        wrote on sidst redigeret af
                                        #159

                                        God morgen. 🙂

                                        1 Reply Last reply
                                        0
                                        • B Offline
                                          B Offline
                                          bibob
                                          wrote on sidst redigeret af
                                          #160

                                          BCMA- CAR-T. JNJ 4528. https://www.onclive.com/web-exclusives/jnj4528-boasts-high-response-rate-in-relapsedrefractory-myeloma?utm_medium=email&utm_campaign=ONCSS MCL CC eNews NO BANNER 2-6-20 NON-US SEND&utm_content=ONCSS MCL CC eNews NO BANNER 2-6-20 NON-US SEND+CID_b62c0ef5d3c78a81dc8c89fb922e8fc8&utm_source=CM ONCLIVE&utm_term=JNJ-4528 Boasts High Response Rate in RelapsedRefractory Myeloma

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger